2026-06-24

Silver volume spike — 3.2× the 20-day average (294 vs 91 avg)

Platinum volume spike — 12.4× the 20-day average (148 vs 11 avg)

Cocoa bull 9.6% vs prior close ($4,545.00 → $4,982.00)

Silver bear 7.2% vs prior close ($62.02 → $57.57)

RBOB Gasoline bear 6.0% vs prior close ($2.96 → $2.78)

OSINT: Escalating Ukraine Geopolitical Tensions Raise Market Risk

Gold -2.75%: significant decline on the session

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

Oil -4.40%: significant decline on the session

OSINT: Iran Deploys 6,200‑ton Offshore Oil Platform in Persian Gulf

Gold -2.60%: significant decline on the session

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

Oil -4.02%: significant decline on the session

OSINT: Russia's MAGN entity hit by new sanctions, market eyes impact

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

OSINT: Canadian Dollar Down 30% vs USD Since GFC

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

Platinum bear 4.6% vs prior close ($1,660.90 → $1,585.00)

WTI Crude Oil bear 4.6% vs prior close ($73.21 → $69.86)

Sugar No. 11 bull 4.4% vs prior close ($13.42 → $14.01)

ETH ETF inflow of $379M — institutional buying

BTC ETF inflow of $2123M — institutional buying

ETH open interest +208.2% — OI surge

SOL open interest +244.7% — OI surge

BTC open interest -67.4% — OI collapse

BTC open interest +90.5% — OI surge

SOL open interest -57.4% — OI collapse

ETH open interest +228.0% — OI surge

SPYx/USDC has $116.9M 24h volume on $1174K liquidity (100x turnover): thin market, elevated slippage

SPYx/USDC has $92.7M 24h volume on $1612K liquidity (57x turnover): thin market, elevated slippage

ETH open interest +200.1% — OI surge

BTC open interest -39.6% — OI collapse

SOL open interest +136.4% — OI surge

BTC open interest +213.1% — OI surge

SOL open interest +133.1% — OI surge

ETH open interest -66.6% — OI collapse

SOL DEX volume/liquidity ratio elevated (1.25x): on-chain trade volume 1.25x liquidity

Phase 3 trial terminated early — ELI A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 Wit

Phase 3 trial terminated early — ELI A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY30

Phase 3 trial terminated early — BRISTOL A Study of Vinflunine in Patients With Gastric Cancer

Phase 3 trial terminated early — BRISTOL Anti-Oxidant Therapy In Chronic Renal Insufficiency (ATIC) Study

Phase 3 trial terminated early — BRISTOL Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-h

Phase 3 trial terminated early — BIOGEN A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in

Phase 3 trial terminated early — AMGEN Impact of LDL-cholesterol Lowering on Platelet Activation

Phase 3 trial terminated early — AbbVie Study Of Diabetic Nephropathy With Atrasentan

Phase 3 trial terminated early — Merck Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IF

Phase 3 trial terminated early — Merck Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Tre

Phase 3 trial terminated early — Merck Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (I

Phase 3 trial terminated early — Merck Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monoth

Phase 3 trial terminated early — PFIZER Effects of Atorvastatin on Myonecrosis

Phase 3 trial terminated early — PFIZER Ziprasidone And Olanzapine's Outcomes In Mania

Phase 3 trial terminated early — PFIZER Study Evaluating The Safety Of Xyntha In Usual Care Settings

Phase 3 trial terminated early — PFIZER Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine

Phase 3 trial terminated early — PFIZER Gabapentin for the Treatment of Neuroleptic-Induced Tremor

Phase 3 trial terminated early — PFIZER Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavi

Phase 3 trial terminated early — PFIZER A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of

Phase 3 trial terminated early — GILEAD ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associ

Phase 3 trial terminated early — GILEAD Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

Debt issued for acquisition financing — deal likely imminent

BITCOIN — speculators net long (+2.5σ vs 52w mean) — contrarian bear signal

HARTFORD INSURANCE GROUP, INC. search volume spiked +100 pts — unusual interest

Callaway Golf Co search volume spiked +100 pts — unusual interest

People Inc search volume spiked +25 pts — unusual interest

Q1-2026: Beat consensus by 106.2% — EPS $0.08 vs $0.0388 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0102 estimate

Q3-2025: Beat consensus by 281.2% — EPS $0.17 vs $0.0446 estimate

Q2-2025: Missed consensus by 16.3% — EPS $0.1 vs $0.1195 estimate

Q4-2025: Beat consensus by 10.8% — EPS $2.62 vs $2.3636 estimate

Q2-2025: Beat consensus by 15.5% — EPS $3.09 vs $2.6752 estimate

Q1-2026: Beat consensus by 11.9% — EPS $3.04 vs $2.7166 estimate

Q3-2025: Beat consensus by 9.4% — EPS $2.5 vs $2.2855 estimate

Q3-2025: Beat consensus by 13.7% — EPS $0.33 vs $0.2902 estimate

Q4-2025: Beat consensus by 10.8% — EPS $0.47 vs $0.4241 estimate

Q2-2025: Beat consensus by 21.9% — EPS $0.38 vs $0.3118 estimate

Q1-2026: Missed consensus by 11.2% — EPS $0.79 vs $0.8901 estimate

Q3-2024: Missed consensus by 30.3% — EPS $69.68 vs $99.99 estimate

Q1-2025: Beat consensus by 193.3% — EPS $13.19 vs $-14.14 estimate

Q2-2025: Missed consensus by 17.1% — EPS $47.75 vs $57.57 estimate

Q4-2024: Missed consensus by 52.4% — EPS $-50.78 vs $-33.33 estimate

Q2-2025: Beat consensus by 5.7% — EPS $2.7 vs $2.5553 estimate

Q1-2026: Missed consensus by 218.5% — EPS $-0.15 vs $-0.0471 estimate

Q2-2025: Beat consensus by 37.0% — EPS $-0.14 vs $-0.2222 estimate

Q3-2025: Missed consensus by 375.2% — EPS $-0.48 vs $-0.101 estimate

Q4-2025: Missed consensus by 122.8% — EPS $-0.18 vs $-0.0808 estimate

Q4-2025: Beat consensus by 5.9% — EPS $3.15 vs $2.9742 estimate

Q1-2026: Beat consensus by 6.1% — EPS $3.22 vs $3.034 estimate

Q2-2025: Beat consensus by 5.2% — EPS $2.78 vs $2.6428 estimate

Q2-2023: Beat consensus by 21.6% — EPS $-6 vs $-7.65 estimate

Q1-2023: Missed consensus by 17.6% — EPS $-9 vs $-7.65 estimate

Q4-2022: Missed consensus by 7.8% — EPS $-16.5 vs $-15.3 estimate

Q3-2023: Beat consensus by 26.5% — EPS $-4.5 vs $-6.12 estimate

Q3-2025: Beat consensus by 16.0% — EPS $0.55 vs $0.4743 estimate

Q4-2025: Missed consensus by 25.8% — EPS $0.43 vs $0.5794 estimate

Q4-2025: Beat consensus by 19.8% — EPS $0.29 vs $0.2421 estimate

Q3-2025: Beat consensus by 6.3% — EPS $0.23 vs $0.2163 estimate

Q3-2025: Beat consensus by 50.5% — EPS $-0.02 vs $-0.0404 estimate

Q4-2025: Beat consensus by 34.0% — EPS $-0.02 vs $-0.0303 estimate

Q2-2025: Beat consensus by 40.6% — EPS $-0.03 vs $-0.0505 estimate

Q4-2025: Beat consensus by 10.2% — EPS $2.04 vs $1.8506 estimate

Q2-2025: Beat consensus by 20.7% — EPS $1.84 vs $1.5247 estimate

Q1-2026: Beat consensus by 25.8% — EPS $2.13 vs $1.6935 estimate

Q3-2025: Beat consensus by 15.4% — EPS $1.96 vs $1.6984 estimate

Q1-2026: Missed consensus by 58.3% — EPS $0.08 vs $0.1919 estimate

Q2-2025: Beat consensus by 18.8% — EPS $0.1 vs $0.0842 estimate

Q3-2025: Beat consensus by 246.5% — EPS $0.35 vs $0.101 estimate

Q4-2025: Beat consensus by 293.3% — EPS $0.47 vs $0.1195 estimate

Q4-2025: Missed consensus by 11.6% — EPS $1.68 vs $1.8999 estimate

Q2-2025: Missed consensus by 6.7% — EPS $4.524 vs $4.8468 estimate

Q1-2026: Beat consensus by 9.3% — EPS $1.87 vs $1.7104 estimate

Q3-2025: Missed consensus by 6.1% — EPS $3.98 vs $4.2381 estimate

Q1-2027: Beat consensus by 5.7% — EPS $1.93 vs $1.8251 estimate

Q2-2026: Beat consensus by 9.7% — EPS $2 vs $1.823 estimate

Q2-2025: Beat consensus by 10.1% — EPS $1.27 vs $1.1531 estimate

Q1-2026: Beat consensus by 12.2% — EPS $1.68 vs $1.4969 estimate

Q3-2025: Beat consensus by 6.8% — EPS $1.37 vs $1.2829 estimate

Q4-2025: Beat consensus by 19.4% — EPS $1.5 vs $1.2568 estimate

Q2-2025: Beat consensus by 14.0% — EPS $0.2073 vs $0.1819 estimate

Q2-2026: Missed consensus by 7.6% — EPS $0.1799 vs $0.1946 estimate

Q1-2026: Missed consensus by 6.0% — EPS $0.15 vs $0.1596 estimate

Q2-2025: Missed consensus by 27.2% — EPS $0.26 vs $0.3573 estimate

Q3-2025: Missed consensus by 18.8% — EPS $0.24 vs $0.2956 estimate

Q4-2025: Missed consensus by 412.4% — EPS $-1.03 vs $0.3297 estimate

Q3-2023: Missed consensus by 31.8% — EPS $0.16 vs $0.2346 estimate

Q3-2024: Missed consensus by 15.0% — EPS $0.26 vs $0.306 estimate

Q2-2023: Missed consensus by 27.4% — EPS $0.2 vs $0.2754 estimate

Q2-2026: Missed consensus by 5.4% — EPS $0.38 vs $0.4017 estimate

Q3-2026: Missed consensus by 39.0% — EPS $0.27 vs $0.4429 estimate

Q3-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0135 estimate

Q1-2026: Missed consensus by 96.1% — EPS $-0.01 vs $-0.0051 estimate

Q2-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0101 estimate

Q1-2026: Missed consensus by 199.0% — EPS $-0.01 vs $0.0101 estimate

Q3-2025: Missed consensus by 149.5% — EPS $-0.01 vs $0.0202 estimate

Q2-2025: Beat consensus by 119.8% — EPS $0.01 vs $-0.0505 estimate

Q2-2026: Missed consensus by 125.0% — EPS $-0.38 vs $1.5198 estimate

Q1-2026: Missed consensus by 88.6% — EPS $0.25 vs $2.1981 estimate

Q3-2026: Missed consensus by 123.9% — EPS $-0.19 vs $0.7956 estimate

Q4-2026: Missed consensus by 7.8% — EPS $7.7 vs $8.3518 estimate

Q4-2025: Missed consensus by 28.4% — EPS $-1.7009 vs $-1.3251 estimate

Q1-2026: Missed consensus by 42.8% — EPS $-0.3462 vs $-0.2425 estimate

Q2-2025: Beat consensus by 60.6% — EPS $0.123 vs $0.0766 estimate

Q1-2026: Beat consensus by 15.5% — EPS $0.13 vs $0.1126 estimate

Q4-2025: Missed consensus by 63.9% — EPS $0.02 vs $0.0554 estimate

Q3-2025: Beat consensus by 38.4% — EPS $0.12 vs $0.0867 estimate

Q1-2026: Beat consensus by 12.4% — EPS $1.3 vs $1.1565 estimate

Q3-2023: Beat consensus by 51.0% — EPS $-0.05 vs $-0.102 estimate

Q2-2025: Missed consensus by 5586.3% — EPS $-0.29 vs $-0.0051 estimate

Q1-2026: Beat consensus by 16.0% — EPS $-0.33 vs $-0.3927 estimate

Q4-2025: Missed consensus by 58.7% — EPS $-0.68 vs $-0.4284 estimate

Q4-2025: Beat consensus by 10.5% — EPS $0.4428 vs $0.4007 estimate

Q2-2025: Beat consensus by 24.6% — EPS $0.2 vs $0.1605 estimate

Q4-2024: Missed consensus by 5.2% — EPS $0.574 vs $0.6056 estimate

Q4-2025: Beat consensus by 18.8% — EPS $1.22 vs $1.0272 estimate

Q2-2025: Beat consensus by 13.5% — EPS $0.629 vs $0.5542 estimate

Q2-2025: Missed consensus by 74.4% — EPS $0.23 vs $0.8989 estimate

Q1-2026: Beat consensus by 18.2% — EPS $0.8 vs $0.6767 estimate

Q4-2025: Missed consensus by 53.9% — EPS $0.67 vs $1.4544 estimate

Q2-2026: Missed consensus by 8.6% — EPS $0.65 vs $0.711 estimate

Q4-2026: Missed consensus by 9.4% — EPS $0.97 vs $1.0706 estimate

Q1-2027: Beat consensus by 76.5% — EPS $0.03 vs $0.017 estimate

Q3-2026: Beat consensus by 206.1% — EPS $0.06 vs $0.0196 estimate

Q2-2026: Beat consensus by 420.2% — EPS $0.09 vs $0.0173 estimate

Q4-2026: Beat consensus by 65.3% — EPS $0.04 vs $0.0242 estimate

Q1-2025: Missed consensus by 198.0% — EPS $-0.01 vs $0.0102 estimate

Q4-2024: Missed consensus by 100.0% — EPS $0 vs $0.0051 estimate

Q3-2026: Missed consensus by 58.6% — EPS $-3.26 vs $-2.0553 estimate

Q2-2026: Missed consensus by 874.0% — EPS $-6.11 vs $-0.6273 estimate

Q1-2026: Beat consensus by 15.7% — EPS $-0.55 vs $-0.6528 estimate

Q2-2025: Beat consensus by 50.5% — EPS $0.22 vs $0.1462 estimate

Q1-2026: Beat consensus by 12.0% — EPS $0.24 vs $0.2142 estimate

Q4-2025: Beat consensus by 21.4% — EPS $0.26 vs $0.2142 estimate

Q3-2025: Missed consensus by 15.2% — EPS $0.16 vs $0.1887 estimate

Q1-2026: Missed consensus by 14.8% — EPS $-1.17 vs $-1.0196 estimate

Q2-2025: Beat consensus by 55.4% — EPS $-0.15 vs $-0.3363 estimate

Q3-2025: Missed consensus by 29.3% — EPS $-0.51 vs $-0.3944 estimate

Q4-2025: Missed consensus by 20.8% — EPS $-0.93 vs $-0.7701 estimate

Q2-2026: Missed consensus by 9.2% — EPS $0.68 vs $0.7486 estimate

Q2-2026: Beat consensus by 17.1% — EPS $1.97 vs $1.6817 estimate

Q3-2026: Beat consensus by 13.1% — EPS $1.27 vs $1.1228 estimate

Q1-2026: Beat consensus by 10.2% — EPS $1.95 vs $1.7692 estimate

Q4-2026: Beat consensus by 11.7% — EPS $1.07 vs $0.9581 estimate

Q2-2019: Missed consensus by 191.3% — EPS $-0.06 vs $-0.0206 estimate

Q4-2019: Beat consensus by 51.5% — EPS $-0.01 vs $-0.0206 estimate

Q3-2019: Missed consensus by 191.3% — EPS $-0.03 vs $-0.0103 estimate

Q3-2009: Beat consensus by 19.6% — EPS $0.58 vs $0.4848 estimate

Q4-2009: Missed consensus by 11.7% — EPS $0.58 vs $0.6565 estimate

Q2-2009: Missed consensus by 7.6% — EPS $0.56 vs $0.606 estimate

Q1-2026: Beat consensus by 37.9% — EPS $0.191 vs $0.1385 estimate